PUBLIC COMPANY
savePFIZER
USupdated 5mo ago
community read0 votes
pipeline
0
marketed
0
phase 3
0
catalysts ytd
0
approvals ytd
0
recalls ytd
0
Pipeline(0)
no pipeline products on record
Upcoming
no upcoming catalysts on record
Recent(90d)
nothing in the last 90 days
view all catalysts →Active trials
- phase3Safety and Effectiveness of Giroctocogene Fitelparvovec or Fidanacogene Elaparvovec in Patients With Hemophilia A or B Respectively
- phase2A Study to Learn About Vepdegestrant When Given With PF-07220060 to People With Advanced or Metastatic Breast Cancer.
- phase1A Study to Learn About the Study Medicine Called PF-08653944 in Otherwise Healthy Chinese Adults With Overweight or Obesity
- phase3Talazoparib + Enzalutamide vs. Enzalutamide Monotherapy in mCRPC
- phase1A Study to Learn About the Study Medicine Called Zavegepant (PF-07930207) in Children With a History of Migraine
- phase3Efficacy and Safety Study of Rimegepant for the Preventative Treatment of Migraine in Pediatric Subjects
- phase2Symbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer
- phase2Symbiotic-GI-13: A Study to Learn About Study Medicine Called PF-08634404 as a Single Treatment and Combination Treatment in Adult Participants With a Liver Cancer Called Hepatocellular Carcinoma, That is Too Advanced to be Removed by Surgery and May Have Spread to Other Parts of the Body.
🐶 Hiring Signal
News
- BMO most bullish on Merck's, bearish on BMS’ plans to contend with patent cliffsBMO Capital Markets is more impressed by Merck’s plans to replace lost Keytruda revenue than on Bristol Myers Squibb’s efforts to fill the expected void that will come from loss of exclusivity for…biospace · 2d ago
- Foghorn cuts 40% of workforceFollow along as BioSpace tracks job cuts and restructuring initiatives.biospace · 2d ago
- Sanofi, Regeneron broaden alliance to find their next DupixentThe deal carries a $1 billion upfront payment and tasks the two companies to develop long-acting antibody drugs that go after the same targets as their blockbuster anti-inflammation agent.biopharma_dive · 3d ago
- Pfizer’s eczema drug clears skin in mid-stage trialDetailed results are competitive with Dupixent and Ebglyss, but the drug lacks differentiation amid an increasingly competitive landscape, one analyst argued.biopharma_dive · 3d ago
- STAT+: Invivyd’s pursuit of a Covid vaccine alternative gets a lift, but an FDA hurdle may awaitThe small biotech company Invivyd is developing an injectable, low-dose monoclonal antibody to protect against Covid.stat · 3d ago
- BioNTech to close German manufacturing plants after failing to find buyersTime has run out on BioNTech's bid to locate buyers for sites in Idar-Oberstein, Marburg and Tübingen. Including staff at a Singapore plant also slated for closure, the move could impact 1,860 jobs.biospace · 4d ago
- AstraZeneca invests $2B in Summit, gaining ‘seat at the table’ for PD-1/VEGF drug pushThe equity investment comes alongside a deal to test Summit’s ivonescimab alongside potentially many AstraZeneca drugs — but doesn’t hand the pharmaceutical company any ownership rights.biopharma_dive · 5d ago
- 6 immunology targets to sustain a mammoth I&I marketJohnson & Johnson, Pfizer, Argenx and more are unlocking new immunology targets and looking to improve on existing ones in an attempt to catch some of the magic brought about by AbbVie’s Humira and…biospace · 6d ago
- Genentech makes $1.5B+ deal with AI heavyweight Earendil for cancer bispecificsGenentech's agreement with Earendil Labs came the same day its parent company, Roche, inked a cardiometabolic and renal deal with Atavistik Bio for up to $2 billion.biospace · 9d ago
- Novo inks $1.3B Nanexa deal to unlock long-acting obesity injectablesNovo has struck a 1.17 billion euro ($1.3 billion) deal to combine Nanexa’s long-acting injectable drug delivery platform with its obesity and Type 2 diabetes drugs.fiercebiotech · 9d ago
comments(0)
5-min edit window · permanent after that